Cannabinoids and hallucinogens for headache

Headache

Volumn 53, Issue 3, 2013, Pages 447-458

  McGeeney, Brian E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cannabinoid; cluster headache; hallucinogen; lysergic acid diethylamide; migraine; psilocybin

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANANDAMIDE; CANNABICYCLOHEXANOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DEXTROMETHORPHAN; DRONABINOL; GLUTAMIC ACID; INDICAN; KETAMINE; LYSERGIDE; MESCALINE; METHYSERGIDE; N,N DIMETHYLTRYPTAMINE; NABIXIMOLS; NORADRENALIN; PLACEBO; PROTEIN C FOS; PSILOCYBINE; PSYCHOTROPIC AGENT; SEROTONIN 2A RECEPTOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANOREXIA; ANXIETY DISORDER; CANCER PAIN; CHROMOSOME 6; CHRONIC DAILY HEADACHE; CIONA INTESTINALIS; CLINICAL TRIAL (TOPIC); CLUSTER HEADACHE; DROSOPHILA; DRUG ABUSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSPHORIA; GENERAL PRACTITIONER; HEADACHE; HUMAN; HYPERSENSITIVITY; MIGRAINE; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEUROPATHY; NONHUMAN; PARAMECIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME; REVIEW; SPASTICITY; ULTRAVIOLET B RADIATION;

CANNABINOIDS; HALLUCINOGENS; HEADACHE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HISTORY, MEDIEVAL; HUMANS;

EID: 84875236098     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12025     Document Type: Review

References (87)

1. Robson P, ed. Forbidden Drugs, 2nd edn. Oxford, England: Oxford University Press; 1996: 66.
2. Russo E,. Cannabis for migraine treatment: The once and future prescription? An historical and scientific review [Review]. Pain. 1998; 76: 3-8.
3. Li HL,. An archaeological and historical account of cannabis in China. Econ Bot. 1974; 28: 437-448.
4. Dwarakanath C,. Use of opium and cannabis in the traditional systems of medicine in India. Bull Narc. 1965; 17: 15-19.
5. Walton RP,. History of the hashish vice. In:, Walton RP, ed. Marihuana America's New Drug Problem. Philadelphia, PA: Lippincott; 1938: 11.
6. O'Shaughnessy WB,. On the preparations of the Indian hemp, or gunjah. Trans Med Phys Soc Bengal. 1838-1840; 8: 71-102.
7. Clendinning J,. Observations on the medical properties of the cannabis sativa of India. Med Chir Trans. 1843; 26: 188-210.
8. Greene R,. Cannabis indica in the treatment of migraine. Practitioner. 1872; 41: 267-270.
9. Reynolds JR,. On the therapeutic uses and toxic effects of cannabis indica. Lancet. 1890; 135: 637-638.
10. Fankhauser M,. Haschish als medikament: Zur Bedeutung von cannabis sativa in der westlichen Medizin. Pharmacy dissertation. Bern: Universittat Bern; 1996: 163.
11. Mackenzie S,. Remarks on the value of Indian hemp in the treatment of a certain type of headache. Br Med J. 1887; 1: 97-98.
12. Farlow JW,. On the use of Belladonna and cannabis indica by the rectum in gynecological practice. Boston Med Surg J. 1889; 120: 507-509.
13. Osler W, McCrae T, eds. Principles and Practice of Medicine, 8th edn. New York: D. Appleton and Co; 1916: 1089.
14. Bragman LJ,. The weed of insanity. Med J Rec. 1925; 122: 416-418.
15. Cary EH,. Report of committee on legislative activities. JAMA. 1937; 108: 2214-2215.
16. Robson P, ed. Forbidden Drugs, 3rd edn. Oxford, England: Oxford University Press; 2009: 62.
17. Grinspoon L, Bakalar J, eds. Marihuana the Forbidden Medicine. New Haven, CT: Yale University Press; 1993.
18. Grinspoon L, Bakalar JB,. Marihuana as medicine: A plea for reconsideration. JAMA. 1995; 273: 1875-1876.
19. De Petrocellis L, Di Marzo V,. An introduction to the endocannabinoid system: From the early to the latest concepts [Review]. Best Pract Res Clin Endocrinol Metab. 2009; 23: 1-15.
20. Anday JK, Mercier RW,. Gene ancestry of the cannabinoid receptor family. Pharmacol Res. 2005; 52: 463-466.
21. Zhang WJ, Bjorn LO,. The effect of ultraviolet radiation on the accumulation of medicinal compounds in plants. Fitoterapia. 2009; 80: 207-218.
22. Lydon J,. The effects of ultraviolet-B radiation on the growth, physiology and cannabinoid production of cannabis sativa L. Dissertation for Ph.D. University of Maryland. 1985.
23. Fu J, Bottegoni G, Sasso O, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci. 2011; 15: 64-69.
24. Greco R, Gasperi V, Maccarrone M, Tassorelli C,. The endocannabinoid system and migraine. Exp Neurol. 2010; 224: 85-91.
25. Kraft B,. Is there any clinically relevant cannabinoid-induced analgesia? Pharmacology. 2012; 89: 237-246.
26. Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interaction in chronic pain. Nature. 2011; 90: 844-851.
27. Gardner EL,. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol Biochem Behav. 2005; 8: 263-284.
28. Oleson EB, Cheer JF,. A brain on cannabinoids: The role of dopamine release in reward seeking. Cold Spring Harb Perspect Med. 2012; 2: 1-13.
29. Katona I, Freund TF,. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008; 14: 923-930.
30. Hampson AJ, Grimaldi M, Axelrod J, Wink D,. Cannabidol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998; 95: 8268-8273.
31. Fimiani C, Liberty T, Aquirre AJ, et al. Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat. 1999; 57: 23-34.
32. Mechoulam R, Parker LA,. The endocannabinoid system and the brain. Annu Rev Psychol. 2013; 64: 6.1-6.27.
33. Gaoni Y, Mechoulam R,. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86: 1646-1647.
34. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO,. Cannabidiol-recent advances. In:, Lambert DM, ed. Cannabinoids in Nature and Medicine. New York: Wiley-VCH; 2009: 83-101.
35. Schultes RE, Klein WM, Plowman T, Lockwood TE,. Cannabis: An example of taxonomic neglect. Bot Mus Leaf Harv Univ. 1974; 23: 337-367.
36. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007; 32: 1384-1390.
37. Russo EB,. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2004; 25: 31-39.
38. Nyholt DR, Morley KI, Ferreira MA, et al. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am J Hum Genet. 2005; 77: 500-512.
39. Juhasz G, Lazary J, Chase D, et al. Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett. 2009; 461: 116-120.
40. Cupini LM, Bari M, Battista N, et al. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia. 2006; 26: 277-281.
41. Van der Schueren BJ, Van Laere K, Gerard N, et al. Interictal type 1 cannabinoid receptor binding is increased in female migraine patients. Headache. 2011; 52: 433-440.
42. Volfe Z, Dvilansky A, Nathan I,. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985; 5: 243-246.
43. Akerman S, Holland PR, Goadsby PJ,. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-584.
44. Akerman S, Kaube H, Goadsby PJ,. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004; 309: 56-63.
45. Greco R, Gasperi V, Sandrini G, et al. Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia. 2009; 30: 296-302.
46. Schnelle M, Grotenhermen F, Reif M, Gorter RW,. Ergebnisse einer standardisierten Umfrage zur medizinischen Verwendung von Cannabisprodukten im deutschen Sprachraum, [Results of a standardized survey on the medical use of cannabis products in the German-speaking area] [Research in Complementary Medicine]. Forsch Komplementarmed. 1999; 6 (Suppl. 3): 28-36.
47. El-Mallakh RS,. Marijuana and migraine. Headache. 1987; 27: 442-443.
48. Robbins MS, Tarshish S, Solomon S, Grosberg BM,. Cluster attacks responsive to recreational cannabis and dronabinol. Headache. 1999; 49: 914-916.
49. Gieringer D,. Medical use of cannabis: Experience in California. In:, Grotenhermen F, Russo EB, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Binghamton, NY: The Hawthorn Press, Inc; 2002: 143-152.
50. Chen SP, Fuh JL, Wang SJ,. Reversible cerebral vasoconstriction syndrome: Current and future perspectives. Expert Rev Neurother. 2011; 11: 1265-1276.
51. Jaffe JH,. Drug addiction and drug abuse. In:, Gilman AG, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: The MacMillan Publishing Co; 1985: 532-581.
52. Letcher A, ed. Shroom: A Cultural History of the Magic Mushroom. New York: Harper Perennial edition; 2008.
53. Halberstadt AL, Geyer MA,. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2001; 61: 364-381.
54. Quednow BB, Kometer M, Geyer MA, Vollenweider FX,. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012; 37: 630-640.
55. Nichols DE, Nichols CD,. Serotonin receptors. Chem Rev. 2008; 108: 1614-1641.
56. Brande E,. On a poisonous species of Agaric. Lond Med Phys J. 1799; XI: 41-44.
57. Nichols DE,. Hallucinogens. Pharmacol Ther. 2004; 101: 131-181.
58. Studerus E, Gamma A, Kometer M, Vollenweider FX,. Prediction of psilocybin response in healthy volunteers. Plos ONE. 2012; 7: 1-12.
59. Jakab RL, Goldman-Rakic PS,. 5-Hydroxytryptaime2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998; 95: 735-740.
60. De Almeida J, Mengod G,. Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT2A receptors in human and monkey prefrontal cortex. J Neurochem. 2007; 103: 475-486.
61. Lee HM, Roth BL,. Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A. 2012; 109: 1820-1821.
62. Carhart-Harris RL, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012; 109: 2138-2143.
63. Prentiss DW, Morgan FP,. Mescal Butons: Anahalonium Lewinii-Hennings (Lophophora Williamsii Lewinii-Coulter). New York: The Publisher's Printing Co; 1896.
64. Perrine D,. Visions of the night-Western medicine meets peyote, 1887-1899. Heffter Rev Psychedelic Res. 2001; 2: 6-52.
65. Sicuteri F,. Prophylactic treatment of migraine by means of lysergic acid derivatives. Triangle. 1963; 6: 116-125.
66. Ling TM, Buckman J, eds. Lysergic Acid (LSD-25) & Ritalin in the Treatment of Neurosis. London: The Lambarde Press; 1963.
67. Snow O, ed. LSD. Spring Hill, FL: Thoth Press; 2003.
68. Fanciullacci M, Franchi G, Sicuteri F,. Hypersensitivty to lysergic acid diethylamine (LSD-25) and psilocybin in essential headache. Experientia. 1974; 30: 1441-1443.
69. Abramson HA, Rolo A,. Comparison of LSD with methysergide and psilocybin on test subjects. 2nd International Conference on the Use of LSD in Psychotherapy and Alcoholism. 1967. 22:53-73.
70. Bana D,. The half-million dollar man. Headache. 1977; 17: 97-100.
71. Quibell R, Prommer EE, Mihalyo M, et al. Ketamine. J Pain Symptom Manage. 2011; 41: 640-649.
72. Nicolodi M, Sicuteri F,. Exploration of NMDA receptors in migraine: Therapeutic and theoretic implications. Int J Clin Pharmacol Res. 1995; 15: 181-189.
73. Kaube H, Herzog J, Kaufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000; 55: 139-141.
74. Krusz JC,. IM ketamine: Rapidly treating various migraine and headaches in the clinic. Presented at 54th Annual Scientific Meeting of the American Headache Society, Los Angeles, CA. 2012.
75. Horita A, Weber LJ,. The enzymatic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol. 1961; 7: 47-54.
76. Shulgin AT,. Profiles of psychedelic drugs. Psilocybin. J Psychedelic Drugs. 1980; 12: 79.
77. Weil M,. Cluster headache medication use survey. Presented at the 7th annual Clusterbusters meeting in Las Vegas, NV, 2012.
78. Prommer EE,. Ketamine for pain: An update of uses in palliative care. J Palliat Med. 2012; 15: 474-483.
79. Malinovsky JM, Servin F, Cozian A, et al. Ketamine and norketamine plasma concentrations after iv, nasal and rectal administration in children. Br J Anaesth. 1996; 77: 203.
80. Sessa B,. Can psychedelics have a role in psychiatry once again? Br J Psychiatry. 2005; 186: 457-458.
81. Court of Appeals of New Mexico. State V Pratt. No. 24,387. June 14th 2005. Accessed at http://www.caselaw.findlaw.com on Sept 30th 2012.
82. Sewell RA, Halpern JH, Pope HG,. Response of cluster headache to psilocybin and LSD. Neurology. 2006; 66: 1920-1922.
83. Sewell RA,. Unauthorized research on cluster headache. Entheogen Rev. 2008; 16: 117-125.
84. Karst M, Halpern JH, Bernateck M, Passie T,. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series. Cephalalgia. 2010; 30: 1140-1144.
85. Tfelt-Hansen P,. Is BOL-148 hallucinogenic? Cephalalgia. 2011; 31: 634.
86. Richards N, Chapman LF, Goodell H, Wolff HG,. LSD-like delirium following a small amount of its brom analog (BOL-148). Ann Intern Med. 1958; 48: 1082.
87. Karst M, Halpern JH, Bernateck M, Passie T,. Reply to Is BOL-148 hallucinogenic? Cephalalgia. 2011; 31: 635-636.